HEALEY ALS Platform Trial - Master Protocol

Active, Not Recruiting

PHASE2Ages 18+InterventionalTreatment

Merit E. Cudkowicz, MD

~1,500 participants

Updated 2026-07-21 on ClinicalTrials.gov

What's tested:ZilucoplanVerdiperstatCNM-Au8PridopidineSLS-005 TrehaloseABBV-CLS-7262

At a glance

Recruiting sites

0 of 81 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Disease Progression

Measured over 36 Weeks

Amyotrophic Lateral Sclerosis

NCT04297683

This study runs at 81 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Atrium Health
Charlotte, North Carolinano site contact published
Augusta University
Augusta, Georgiano site contact published
Austin Neuromuscular Clinic
Austin, Texasno site contact published
Barrow Neurological Institute
Phoenix, Arizonano site contact published
Baylor College of Medicine
Houston, Texasno site contact published
Beth Israel Deaconess Medical Center
Boston, Massachusettsno site contact published
Cedars-Sinai Medical Center
Los Angeles, Californiano site contact published
Cleveland Clinic
Cleveland, Ohiono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

This trial hasn't published a contact. View it on ClinicalTrials.gov

Disease Progression36 Weeks
Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score and survival.